GlassScriptPhysician profile
Catherine N Torralva
NPI 1760854178
$8,506.52
in general payments reported to CMS, 2019-2025
24 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.65 · 2022: $1,606 · 2023: $2,109 · 2024: $2,340 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,768 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,767.99 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,729.92 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,360.98 | 2022-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,043.82 | 2022-2025 | |
| Lilly USA, LLC | $778.58 | 2022-2025 | Taltz, Ebglyss |
| Ucb, INC. | $642.85 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $616.14 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $508.51 | 2022-2025 | Saphnelo, Flumist Quadrivalent |
| Abbvie INC. | $391.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $319.05 | 2021-2025 | Benlysta, Nucala |
| Pfizer INC. | $212.21 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $159.56 | 2023-2025 | Tyenne, Idacio |
| Genentech USA, INC. | $153.35 | 2023-2025 | Actemra, Gazyva, Rituxan |
| Horizon Therapeutics Plc | $139.36 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $123.91 | 2022-2025 | Orencia |
| Ferring Pharmaceuticals INC. | $58.03 | 2022-2023 | Euflexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $55.40 | 2025 | Tymlos |
| Octapharma USA, INC. | $40.00 | 2024-2025 | Octagam Immune Globulin (Human) |
| Actelion Pharmaceuticals US, INC. | $38.20 | 2022 | |
| Ani Pharmaceuticals, INC. | $32.29 | 2023-2024 | Purified Cortrophin Gel |
| Celltrion USA INC. | $30.55 | 2025 | Vegzelma |
| Invivyd INC | $24.36 | 2025 | Pemgarda |
| Sandoz INC. | $17.01 | 2023 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $16.53 | 2024 | Arcalyst |
| Cumberland Pharmaceuticals, INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Torralva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.